|
|
||||||||||||||
|
|
|||||||||||||||
|
Published Online First: 13 June 2007. doi:10.1136/bjo.2007.121830 British Journal of Ophthalmology 2007;91:1602-1606 Copyright © 2007 by the BMJ Publishing Group Ltd.
Histopathological findings in postmortem eyes after photodynamic therapy for choroidal neovascularisation in age-related macular degeneration: report of two casesS J Kang1, I Schmack2, H E Benson1, H E Grossniklaus1
1 Department of Ophthalmology, Emory Eye Center, Emory University School of Medicine, Atlanta, GA, USA
Correspondence to:
Methods: Two eyes were obtained postmortem from two patients with CNV secondary to AMD. Both of the patients had been treated with PDT. Serial sections through the posterior poles were obtained and stained with haematoxylin-eosin, periodic acid-Schiff, Masson trichrome or phosphotungstic acid haematoxylin (PTAH). Two-dimensional reconstructions were prepared and compared with fluorescein angiograms. Results: The interval between PDT and death was 3 months and 17 months in each patient, respectively. Light-microscopic examination showed that CNV enveloped with retinal pigment epithelium (RPE) in both eyes. The average size of the CNV was 550x280 µm. One eye had combined (subRPE/subretinal) growth pattern CNV, and the other eye had both type I (subRPE) and combined growth pattern CNV. All specimens contained fibrous proliferation and patent vascular channels within the CNV, and there was no thrombus formation within the vascular channels. No apparent abnormalities in the choroid were observed by light microscopy. Conclusions: Although involution with fibrous tissue proliferation occurred, PDT did not result in permanent occlusion of the vascular channels in the CNV. Our findings indicate that PDT may accelerate involution of CNV, thus limiting its size and preserving photoreceptors.
Abbreviations: AMD, age-related macular degeneration; CNV, choroidal neovascularisation; IOL, intraocular lens; PDT, photodynamic therapy; PTAH, phosphotungstic acid haematoxylin; RPE, retinal pigment epithelium
Funding: HEG is a recipient of the Research to Prevent Blindness Senior Scientific Investigator award. This study was supported by a grant from QLT, Vancouver, BC, Canada. The sponsors participated in the study design, in the collection and in the decision to submit the paper for publication.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |